On February 18, 2021, Rousselot, Philippe published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was BiTtEn by Src inhibitors. And the article contained the following:
One ongoing study from the GIMEMA reported the sequential use of dasatinib and blinatumomab as first-line induction and consolidation therapy in Ph1 ALL patients. The complete mol. response rate was up to 60%.5 A few studies reported on the clin. efficacy of TKIs given in combination with blinatumomab. Assi et al reported a retrospective anal. of 12 patients (9 patients with Ph1 ALL including 5 overt relapses and 4 pos. MRD plus 3 chronic myeloid leukemia blast crisis patients including 1 overt relapse and 2 pos. MRD) treated with blinatumomab and ponatinib (n = 8), dasatinib (n = 3), or bosutinib (n = 1). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3
The Article related to blinatumomab lymphoblastic leukemia tyrosine kinase src inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C26H29Cl2N5O3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics